{"id":967842,"date":"2026-05-28T01:03:03","date_gmt":"2026-05-28T05:03:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\/"},"modified":"2026-05-28T01:03:03","modified_gmt":"2026-05-28T05:03:03","slug":"argenx-to-host-myositis-rd-webinar-on-june-23-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\/","title":{"rendered":"argenx to Host Myositis R&D Webinar on June 23, 2026"},"content":{"rendered":"
\n

\n

\n May 28, 2026<\/b><\/p>\n

Amsterdam, the Netherlands<\/b> \u2013 argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled \u201cR&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis\u201d on Tuesday, June 23, 2026, at 2:00pm ET.<\/p>\n

The second webinar in the Company\u2019s \u2018mini\u2019 series highlighting the argenx pipeline and research and development strategy will focus on myositis, an autoimmune rheumatic disease associated with progressive muscle damage and significant patient burden. The argenx team and leading clinicians treating myositis will discuss emerging insights into disease biology, including the role of autoantibodies as key disease drivers, as well as the ALKIVIA clinical program design and the clinical and commercial opportunity for efgartigimod.<\/p>\n

A webcast of the event can be accessed on the Investors section of the argenx website at argenx.com\/investors<\/a>. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.<\/p>\n

\n About argenx<\/b>
\n
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit \u00a0www.argenx.com<\/a>\u00a0 and follow us on\u00a0LinkedIn<\/a>,\u00a0Instagram<\/a>,\u00a0Facebook<\/a>, and\u00a0YouTube<\/a>.<\/p>\n

\n Contacts<\/b>\n <\/p>\n

\n Media:<\/b>\n <\/p>\n

Colin McBean
cmcbean@argenx.com<\/a><\/p>\n

\n Investors:<\/b>\n <\/p>\n

Alexandra Roy
aroy@argenx.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

May 28, 2026 Amsterdam, the Netherlands \u2013 argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled \u201cR&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis\u201d on Tuesday, June 23, 2026, at 2:00pm ET. The second webinar in the Company\u2019s \u2018mini\u2019 series highlighting the argenx pipeline and research and development strategy will focus on myositis, an autoimmune rheumatic disease associated with progressive muscle damage and significant patient burden. The argenx team and leading clinicians treating myositis will discuss emerging insights into disease biology, including the role of autoantibodies as key disease drivers, as well as the ALKIVIA clinical program design and the … <\/p>\n

Continue reading “argenx to Host Myositis R&D Webinar on June 23, 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-967842","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nargenx to Host Myositis R&D Webinar on June 23, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"argenx to Host Myositis R&D Webinar on June 23, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"May 28, 2026 Amsterdam, the Netherlands \u2013 argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled \u201cR&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis\u201d on Tuesday, June 23, 2026, at 2:00pm ET. The second webinar in the Company\u2019s \u2018mini\u2019 series highlighting the argenx pipeline and research and development strategy will focus on myositis, an autoimmune rheumatic disease associated with progressive muscle damage and significant patient burden. The argenx team and leading clinicians treating myositis will discuss emerging insights into disease biology, including the role of autoantibodies as key disease drivers, as well as the ALKIVIA clinical program design and the … Continue reading "argenx to Host Myositis R&D Webinar on June 23, 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-28T05:03:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4NDM4NSM0MDIzOTk0MjUjMjAwMzc3Mg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"argenx to Host Myositis R&D Webinar on June 23, 2026\",\"datePublished\":\"2026-05-28T05:03:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\\\/\"},\"wordCount\":282,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE4NDM4NSM0MDIzOTk0MjUjMjAwMzc3Mg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\\\/\",\"name\":\"argenx to Host Myositis R&D Webinar on June 23, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE4NDM4NSM0MDIzOTk0MjUjMjAwMzc3Mg==\",\"datePublished\":\"2026-05-28T05:03:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE4NDM4NSM0MDIzOTk0MjUjMjAwMzc3Mg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE4NDM4NSM0MDIzOTk0MjUjMjAwMzc3Mg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"argenx to Host Myositis R&D Webinar on June 23, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"argenx to Host Myositis R&D Webinar on June 23, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\/","og_locale":"en_US","og_type":"article","og_title":"argenx to Host Myositis R&D Webinar on June 23, 2026 - Market Newsdesk","og_description":"May 28, 2026 Amsterdam, the Netherlands \u2013 argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled \u201cR&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis\u201d on Tuesday, June 23, 2026, at 2:00pm ET. The second webinar in the Company\u2019s \u2018mini\u2019 series highlighting the argenx pipeline and research and development strategy will focus on myositis, an autoimmune rheumatic disease associated with progressive muscle damage and significant patient burden. The argenx team and leading clinicians treating myositis will discuss emerging insights into disease biology, including the role of autoantibodies as key disease drivers, as well as the ALKIVIA clinical program design and the … Continue reading \"argenx to Host Myositis R&D Webinar on June 23, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-28T05:03:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4NDM4NSM0MDIzOTk0MjUjMjAwMzc3Mg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"argenx to Host Myositis R&D Webinar on June 23, 2026","datePublished":"2026-05-28T05:03:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\/"},"wordCount":282,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4NDM4NSM0MDIzOTk0MjUjMjAwMzc3Mg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\/","name":"argenx to Host Myositis R&D Webinar on June 23, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4NDM4NSM0MDIzOTk0MjUjMjAwMzc3Mg==","datePublished":"2026-05-28T05:03:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4NDM4NSM0MDIzOTk0MjUjMjAwMzc3Mg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4NDM4NSM0MDIzOTk0MjUjMjAwMzc3Mg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/argenx-to-host-myositis-rd-webinar-on-june-23-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"argenx to Host Myositis R&D Webinar on June 23, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/967842","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=967842"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/967842\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=967842"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=967842"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=967842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}